Interleukin‐40 in Systemic Sclerosis: A Treatment‐Sensitive Marker of Immune Modulation Rather Than Disease Activity
Open Access
- 25 July 2026
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (8) , e70678
Abstract
Interleukin‐40 (IL‐40) is a recently identified cytokine primarily produced by activated B cells and implicated in immune regulation across several autoimmune diseases. Although B cell–driven immune dysregulation plays a central role in systemic sclerosis (SSc), the circulating behavior and clinical relevance of IL‐40 in this disease remain poorly defined. To characterize serum IL‐40 levels in patients with SSc and to explore their associations with immunosuppressive treatment exposure, disease subsets, clinical manifestations, and disease activity. Serum IL‐40 levels were measured by ELISA in 41 patients with SSc and 29 age‐ and sex‐matched healthy controls. Patients were stratified according to immunosuppressive treatment status at the time of serum sampling. Clinical features, organ involvement, and disease activity were recorded. Serum IL‐40 levels differed significantly among immunosuppressed SSc patients, untreated SSc patients, and healthy controls ( p < 0.001). Patients receiving immunosuppressive therapy exhibited markedly lower IL‐40 concentrations compared with both untreated SSc patients and healthy controls. In contrast, untreated SSc patients showed IL‐40 levels comparable to controls. Serum IL‐40 levels were not significantly associated with cutaneous disease subtype, interstitial lung disease, dysphagia, or disease activity status. Stratified analyses demonstrated that lower IL‐40 levels in treated patients were observed irrespective of disease activity. Lower circulating IL‐40 levels were observed in immunosuppressed patients irrespective of disease phenotype, organ involvement, or disease activity. These findings support an association between treatment exposure and circulating IL‐40 levels, although longitudinal studies are needed to clarify causality.Keywords
This publication has 17 references indexed in Scilit:
- Potential involvement of IL-40 in kidney disease associated to systemic lupus erythematosusLupus, 2025
- IL-40 is up-regulated in the synovial fluid and cartilage of osteoarthritis patients and contributes to the alteration of chondrocytes phenotype in vitroArthritis Research & Therapy, 2024
- New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritisRMD Open, 2023
- Possible role for IL-40 and IL-40-producing cells in the lymphocytic infiltrated salivary glands of patients with primary Sjögren’s syndromeRMD Open, 2023
- Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profileAnnals of the Rheumatic Diseases, 2020
- Rituximab in systemic sclerosisMedicine, 2019
- Systemic sclerosisThe Lancet, 2017
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2013
- European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteriaAnnals of the Rheumatic Diseases, 2003
- Mycophenolate mofetil and its mechanisms of actionImmunopharmacology, 2000